Gossamer Bio (FRA:4GB) Short Percentage of Float

View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Gossamer Bio's Short Percentage of Float

For the Biotechnology subindustry, Gossamer Bio's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gossamer Bio's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gossamer Bio's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Gossamer Bio's Short Percentage of Float falls into.

Gossamer Bio (FRA:4GB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (FRA:4GB) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

GOSS:USA 4GB:Germany

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio (FRA:4GB) Headlines

No Headlines